Ketamine’s Hidden Side Revealed: New Evidence Shows Direct Opioid Receptor Action

Ketamine has long puzzled researchers because it can act as an anesthetic, painkiller, dissociative, hallucinogen and rapid-acting antidepressant. Most of these diverse effects have traditionally been attributed to its action on the NMDA receptor, a key receptor for the excitatory neurotransmitter glutamate.

For years, however, scientists suspected that this explanation was incomplete. Now, a new study led by pharmacologist Tao Che at Washington University School of Medicine provides detailed structural evidence that ketamine also directly binds to the brain’s opioid receptors.

The findings, published in the journal Nature Structural & Molecular Biology, show ketamine occupying the main binding pockets of human mu and kappa opioid receptors. The discovery helps clarify the drug’s complex mechanism of action and could ultimately influence research into its use for anesthesia, pain management and depression.

Building on decades of clues

Ketamine’s story began with phencyclidine, or PCP, a dissociative anesthetic first developed in the 1950s. Although effective, PCP produced severe side effects, including delirium, hallucinations, psychotic behavior and seizures, prompting researchers to search for safer alternatives.

In the 1960s, chemists modified PCP to create ketamine, which quickly became a valuable anesthetic and later an off-label treatment for severe depression. It was classified primarily as an NMDA receptor antagonist, but early studies hinted that opioid receptors might also be involved.

Research in the late 1970s showed that PCP-like drugs could bind to opioid receptors, while a 1984 study found that naloxone, an opioid blocker, reduced ketamine’s anesthetic effect. However, the evidence remained inconsistent, and direct structural proof that ketamine occupied human opioid receptors was lacking.

Direct binding to opioid receptors

Che’s team examined ketamine’s effects on the three main types of opioid receptors: mu, kappa and delta. Using human receptors expressed in cultured cells, the researchers found that ketamine could bind to and activate all three, with stronger activity at mu and kappa receptors.

The researchers showed that ketamine acts as a partial agonist, meaning that it activates these receptors, but not as strongly as typical opioid drugs used for comparison. This more limited activation may help explain why ketamine does not behave clinically like a conventional opioid.

To visualize the interaction, the team used cryo-electron microscopy. The resulting images revealed ketamine lodged inside the primary binding pockets of mu and kappa receptors — the same general sites targeted by conventional opioid painkillers.

This structural “snapshot” provides direct evidence that ketamine engages opioid receptors rather than affecting them solely through indirect mechanisms. It adds an important piece to the puzzle of how the drug produces its unusually broad range of effects.

Animal tests confirm functional impact

Binding to a receptor does not necessarily mean that the interaction produces a meaningful effect in a living organism, so the researchers also conducted experiments in mice. They administered subanesthetic doses of ketamine and measured how quickly the animals withdrew their tails from warm water.

Mice given ketamine took longer to withdraw their tails, indicating a pain-relieving effect. However, when the animals were first given drugs that block opioid receptors, ketamine’s analgesic effect disappeared.

When ketamine was combined with naloxone, which broadly blocks opioid receptors, or aticaprant, which selectively blocks kappa receptors, the mice responded as though they had not received ketamine. The findings suggest that opioid receptors play an important role in ketamine’s pain-relieving effects.

Beyond a single mechanism

Despite the new evidence involving opioid receptors, ketamine still binds more strongly to NMDA receptors, and this interaction remains central to many of its effects. The emerging picture is therefore not that opioid receptors replace the established NMDA explanation, but that ketamine acts through multiple molecular systems.

In a commentary accompanying the study, neuroscientists Jordi Bonaventura and Michael Michaelides describe a “bifunctional” mechanism involving both NMDA receptor blockade and direct opioid receptor engagement.

The clearest implications currently concern pain management. The mouse experiments support the idea that opioid receptors contribute significantly to ketamine’s analgesic effects, although the precise interaction between opioid and NMDA receptor pathways remains to be determined.

Implications for depression and addiction

Whether ketamine’s opioid activity also contributes to its rapid antidepressant effects remains an open question. Some human studies have suggested that blocking opioid receptors can blunt ketamine’s antidepressant response, but the underlying mechanisms are not yet fully understood.

The new research did not directly examine mood-related outcomes, so further studies will be needed to determine how much of ketamine’s antidepressant action depends on opioid receptor engagement compared with NMDA receptor blockade or other pathways.

The findings also renew attention to ketamine’s potential for misuse and dependence. Previous animal research has linked the mu opioid receptor to ketamine’s reinforcing effects, which can encourage repeated use.

By demonstrating that ketamine can directly bind to and partially activate mu receptors, the study provides a possible molecular connection between some of its therapeutic effects and its abuse potential. However, ketamine dependence is not equivalent to classic opioid addiction because the drug acts across multiple brain systems.

Toward safer next-generation treatments

A clearer understanding of how ketamine simultaneously targets NMDA and opioid receptors could eventually help researchers design improved drugs. One goal would be to preserve its rapid antidepressant and pain-relieving properties while reducing dissociation, hallucinations and the potential for misuse.

The authors suggest that compounds could potentially be designed to balance NMDA and opioid receptor activity more precisely, helping separate therapeutic effects from unwanted ones. The structural information provided by the new study could guide the development of such next-generation molecules.

As ketamine is increasingly used in depression treatment and anesthesia, understanding its mechanisms in greater detail could help inform safer and more targeted therapeutic strategies. The new findings provide a more complete molecular picture of how ketamine acts and open additional avenues for both basic research and drug development.